Crohn’s disease develops through a chain reaction: genetic susceptibility allows environmental triggers to disrupt the intestinal barrier, which exposes the immune system to gut bacteria it would normally ignore, setting off a self-reinforcing cycle of chronic inflammation. Unlike many digestive conditions, this inflammation cuts through the full thickness of the bowel wall and can strike anywhere from the mouth to the anus, though it most commonly targets the end of the small intestine. Understanding each link in this chain reveals why Crohn’s behaves the way it does and why it can be so difficult to control.
Genetic Susceptibility Sets the Stage
More than 240 genetic variants have been linked to Crohn’s disease, but the single most important gene is NOD2. This gene codes for an intracellular sensor that detects a molecule called muramyl dipeptide, a component of bacterial cell walls. Under normal circumstances, NOD2 helps the immune system distinguish harmless gut bacteria from dangerous invaders and keeps the peace between microbes and the intestinal lining.
Three specific mutations in NOD2 are strongly tied to Crohn’s, particularly to inflammation in the ileum (the last section of the small intestine). These mutations sit in the part of the gene responsible for recognizing bacterial fragments. When that recognition system malfunctions, the body loses its ability to manage the trillions of bacteria living in the gut. Harmful bacteria can multiply unchecked, and immune tolerance to normal, commensal microbes breaks down.
Another key gene, ATG16L1, plays a role in autophagy, the cellular recycling process that clears out damaged components and destroys bacteria that sneak inside cells. When ATG16L1 is impaired, intracellular bacteria survive longer than they should, fueling a persistent immune response. Together, these genetic defects don’t cause Crohn’s on their own, but they prime the intestine to overreact when the right environmental trigger comes along.
The Intestinal Barrier Breaks Down
The lining of the gut acts as a selective barrier. Cells are stitched together by tight junction proteins, including occludin, several types of claudins, and a molecule called JAM-A. In people with Crohn’s, the expression and positioning of these barrier-forming proteins is disrupted. Occludin, claudin-3, claudin-5, and claudin-8 all decrease, while claudin-2, a “pore-forming” protein that makes the barrier leakier, increases.
At the molecular level, enzymes phosphorylate (activate) components of the cell’s internal scaffolding, causing the tight junctions to contract and pull apart. This opens gaps between cells, creating paracellular pathways that allow bacteria, bacterial fragments, and food antigens to slip through the lining and reach the immune cells waiting on the other side. This increased permeability is sometimes called “leaky gut,” and in Crohn’s disease it is both a consequence of inflammation and a driver of it, creating a feedback loop that perpetuates damage.
Immune Dysregulation Drives Chronic Inflammation
Once bacterial material breaches the intestinal barrier, the immune system mounts a response that, in a healthy person, would resolve quickly. In Crohn’s disease, that response never fully shuts off. The inflammation was traditionally attributed to a specific type of immune cell called Th1 cells, which produce inflammatory signaling molecules. More recent work has revealed that Th17 cells are equally important. These cells develop under the influence of a cascade of signals, and genome-wide association studies have identified the IL-23 receptor gene and five other genes involved in Th17 cell development as Crohn’s susceptibility genes.
The cytokine IL-23 has emerged as a central player. It was once thought that IL-12 drove the Th1 response in Crohn’s, but many of IL-12’s effects are now believed to be mediated by IL-23 instead, since the two cytokines share a common subunit. IL-23 promotes the survival and expansion of Th17 cells, which in turn release their own inflammatory signals, recruiting still more immune cells to the gut wall. TNF-alpha, another major inflammatory cytokine, amplifies the damage by promoting cell death in the intestinal lining and stimulating the production of additional inflammatory mediators. This is why therapies that block TNF-alpha or the IL-12/IL-23 pathway can be effective: they interrupt the self-perpetuating inflammatory loop at key nodes.
Microbiome Shifts Fuel the Cycle
The gut microbiome in Crohn’s disease looks fundamentally different from a healthy one. The pattern is consistent across dozens of studies: beneficial, anti-inflammatory bacteria decline while potentially harmful species expand. The most reliably depleted species is Faecalibacterium prausnitzii, a bacterium that produces short-chain fatty acids critical for nourishing the intestinal lining and calming immune responses. Other beneficial groups that decrease include Roseburia, Bifidobacterium adolescentis, Lactobacillus species, and members of the Clostridium clusters IV and XIVa.
Filling the void left by these protective microbes are species associated with inflammation. E. coli, particularly adherent-invasive strains, consistently increases in the Crohn’s gut, along with Ruminococcus gnavus, Fusobacterium, Campylobacter species, and members of the Enterobacteriaceae family. This shift, known as dysbiosis, isn’t just a bystander effect. The loss of short-chain fatty acid producers weakens the intestinal barrier further, and the expansion of invasive bacteria provides a constant stream of immune-activating signals. Whether dysbiosis is a cause or consequence of Crohn’s remains debated, but the evidence strongly suggests it acts as both, feeding back into the cycle of barrier breakdown and immune activation.
Transmural Inflammation and Tissue Damage
What distinguishes Crohn’s from many other inflammatory conditions is the depth of its damage. While ulcerative colitis affects only the innermost lining of the colon, Crohn’s inflammation is transmural, meaning it extends through all layers of the bowel wall, from the mucosa on the inside to the serosa on the outside. This full-thickness involvement is responsible for many of the disease’s most serious complications.
The inflammation also has a characteristic pattern. It tends to appear in patches, with inflamed segments (called skip lesions) separated by stretches of completely normal-looking bowel. Ulcers begin at the surface and progressively burrow deeper. Over time, the combination of deep ulcers and swollen, intact tissue between them creates a cobblestone appearance on the intestinal lining, a hallmark visible during endoscopy. Non-caseating granulomas, clusters of immune cells that wall off perceived threats, are another defining histological feature, though they aren’t present in every patient.
How Fistulas and Strictures Develop
The transmural nature of Crohn’s inflammation sets the stage for two of its most disabling complications: fistulas and strictures. Fistulas are abnormal tunnels that connect the intestine to other organs, to the skin surface, or to other loops of bowel. They begin at a site where inflammation has created a defect in the intestinal lining. From there, the process depends on a phenomenon called epithelial-to-mesenchymal transition (EMT), in which intestinal lining cells lose their normal characteristics and transform into mobile, fibroblast-like cells.
Under normal conditions, EMT helps with wound repair. In Crohn’s, however, conventional wound healing is already impaired, and the process goes awry. The transformed cells burrow into deeper layers of the gut wall, activating enzymes that break down the surrounding tissue. TNF and IL-13 create a self-amplifying loop, stimulating their own production and driving the invading cells deeper. The result is a tube-like tract that can eventually reach another organ or the skin surface.
Strictures form through a parallel but distinct process. Chronic cycles of inflammation and attempted healing deposit layer upon layer of scar tissue (fibrosis) in the bowel wall. Over months or years, this scarring narrows the intestinal passage, potentially causing blockages. Unlike active inflammation, established fibrotic strictures don’t respond well to anti-inflammatory medications, which is why they often require surgical intervention.
Environmental Triggers
Smoking is the best-studied environmental risk factor for Crohn’s disease, and its effects illustrate how external exposures interact with the pathophysiology described above. Cigarette smoke damages the intestinal lining directly, increasing the rate of cell death in the specialized tissue overlying immune surveillance sites called Peyer’s patches. This barrier damage exposes the immune system to gut bacteria it would otherwise never encounter.
Simultaneously, smoking triggers a significant increase in immune cell recruitment to the ileum, including dendritic cells, macrophages, and both CD4+ and CD8+ T cells. It upregulates inflammatory chemokines that are specifically implicated in Crohn’s pathogenesis. Smoke also impairs blood flow to the intestinal lining by altering the microvasculature, promoting localized oxygen deprivation that compounds tissue injury. Particulate matter from cigarettes can reach the ileum and alter the composition of the microbiome, affecting bacterial clearance and further increasing intestinal permeability. In short, smoking simultaneously worsens nearly every link in the pathophysiological chain.
Urbanization and industrialization also play a role. Crohn’s prevalence is rising fastest in newly industrialized regions. In Brazil, for example, more urbanized areas like São Paulo have three times the prevalence of less developed regions. The specific mechanisms likely involve changes in diet, antibiotic exposure, sanitation practices, and other factors that collectively reshape the gut microbiome and immune development.
Effects Beyond the Gut
The inflammatory cascade in Crohn’s disease doesn’t stay confined to the intestine. Extraintestinal manifestations most commonly affect the joints, skin, and eyes. Some of these, including peripheral arthritis, mouth ulcers, and a type of eye inflammation called episcleritis, flare in sync with intestinal disease activity and improve when gut inflammation is controlled. Others, including spinal arthritis (ankylosing spondylitis), a deeper form of eye inflammation called anterior uveitis, and a liver condition called primary sclerosing cholangitis, follow their own course independent of intestinal flares.
The mechanisms behind these distant effects aren’t fully mapped, but they likely involve circulating immune cells and inflammatory cytokines that were activated in the gut but travel through the bloodstream to other tissues. In some cases, immune cells primed against intestinal antigens may cross-react with proteins found in joints, skin, or the biliary tract. This systemic dimension of Crohn’s underscores that the disease is not simply a bowel condition but a systemic inflammatory disorder with intestinal predominance.
How Treatments Target These Pathways
Modern Crohn’s therapies are designed to interrupt the specific pathways described above. Anti-TNF therapies neutralize TNF-alpha, blocking one of the central inflammatory cytokines that drives tissue damage, recruits immune cells, and promotes fistula formation. Therapies targeting the shared subunit of IL-12 and IL-23 suppress both Th1 and Th17 cell activation simultaneously, addressing the two main arms of the adaptive immune response. Newer agents that block only the IL-23-specific subunit offer a more targeted approach, dampening Th17-driven inflammation while leaving IL-12 pathways less affected.
A separate class of therapies targets immune cell trafficking rather than cytokines. These drugs block integrins, the surface molecules that immune cells use to exit the bloodstream and migrate into gut tissue. By preventing this migration selectively in the intestine, they reduce inflammation locally without broadly suppressing the immune system elsewhere in the body. Each of these treatment categories maps directly onto a specific node in the pathophysiological cascade, which is why different patients respond to different therapies depending on which pathways are most active in their particular disease.